Enter assignee name

% Expired Patents = 28.6

EPO Patents = 18

Forward Citations = 84

Loading Chart...

4 inventors (with patents filed for the assignee):

Christophe Bonny (8 out of 24 patents)

Catherine Deloche (6 out of 8 patents)

Jean-Marc Combette (6 out of 8 patents)

4. Claire Abadie (2 out of 4 patents)

14 patents: Sort by Forward Citations

1. 11779628 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2023-10-10),

2. 11331364 - Use for JNK inhibitor molecules for treatment of various diseases (2022-05-17),

3. 10967038 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases (2021-04-06),

4. 10624948 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2020-04-21),

5. 10596223 - JNK inhibitor molecules for treatment of various diseases (2020-03-24),

6. 10023615 - Efficient transport into white blood cells (2018-07-17),

7. 9624267 - JNK inhibitor molecules (2017-04-18),

8. 9610330 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2017-04-04),

9. 9290538 - Cell-permeable peptide inhibitors of the JNK signal transduction pathway (2016-03-22),

10. 9180159 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases (2015-11-10),

11. 9150618 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases (2015-10-06),

12. 9006185 - Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases (2015-04-14),

13. 8981052 - JNK inhibitor molecules (2015-03-17),

14. 8748395 - Cell-permeable peptide inhibitors of the JNK signal transduction pathway (2014-06-10),

XIGEN INFLAMMATION LTD. is a leading biotechnology company focused on developing innovative therapeutics for the treatment of inflammation-related diseases. With a specific emphasis on chronic inflammation, our dedicated team of scientists and researchers work tirelessly to discover and develop novel drugs and therapies that aim to improve the lives of patients. Through cutting-edge research, strategic partnerships, and a commitment to scientific excellence, we strive to make a significant impact in the field of inflammation research.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

14 Patents

#6 in Limassol

#12 in Cyprus

#42,135 in the World

Limassol, Cyprus

Xigen Inflammation Ltd.

Forward Citations = 84

4 inventors:

Christophe Bonny (8 out of 24 patents)

Catherine Deloche (6 out of 8 patents)

Jean-Marc Combette (6 out of 8 patents)

4. Claire Abadie (2 out of 4 patents)

Please report any incorrect information to [email protected]